

Bespoke Extracts, Inc. (BSPK)

None; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001409197

Bespoke Extracts, Inc. BSPK; healthcare		
Grade	None 4 of 14 inputs computable; 7 are required	
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$359,088	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	late filer, thin data not computable: dilution, short runway, distress, fortress balance sheet	
Inputs computable	4 of 14	
Graded from	filings received through Apr 21, 2025 536 days before the rescan; latest periodic filing 10-Q received Nov 12, 2025	
Price used in grade	None	

Letter at every rescan

Oct 6, 2026 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	

Business, in the company's words

opening of Item 1 of the 10-K received Apr 21, 2025

a Nevada corporation. The Company's Common Stock (as hereinafter defined) is traded in the United States on the OTCQB (the "OTCQB") under the symbol "BSPK." The Company has one wholly-owned subsidiary, Bespoke Extracts Colorado, LLC ("Bespoke Colorado"). Bespoke began operations in the cannabis industry in 2023 upon the acquisition of a state-licensed adult-use marijuana infused products business in Aurora, Colorado. The Company has since begun producing pre-rolled marijuana cigarettes, or "pre-rolls".

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 2.0						
Gross profitability		126.1%	32.2%	2.2	372	2024-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(209.6%)	(6.6%)	1.9	811	2024-12-31

Gross margin stability, five years	not computable	2.8 pts	five consecutive annual gross margins are required
Solvency, sleeve percentile 98.5			
Twelve-month failure probability	not computable	0.07%	market price is missing at 2025-09-30
Altman Z double-prime	 (276.64)	(0.31)	99.1 756 2024-12-31
Net debt to EBITDA	not computable	1.82x	one or more required annual facts are missing latest aligned inputs end 2020-08-31; latest annual assets end 2024-12-31
Interest coverage	not computable	(4.51x)	2024-12-31
Current ratio	 0.15x	2.96x	98.0 839 2024-12-31
Growth and financing			
Revenue growth, three-year compound	not computable	10.0%	four consecutive annual observations are required
Free cash flow growth, three-year compound	not computable	10.9%	four consecutive annual FCF observations are required; found 3
Reinvestment rate	not computable	37.1%	one or more required annual facts are missing
Asset growth, three years	not computable	2.1%	four consecutive annual observations are required
Net share issuance, one year	not computable	2.5%	raw and split-adjusted prices do not align at 2025-03-27

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 6 NT 10-K/Q filings in the last eight quarters
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-09 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	8.0%	
Distance from 52-week high	not computable	(31.4%)	
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	not computable	(0.14)	

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2024-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	331 (10-Q received Nov 12, 2025)
Median daily dollar volume, 63 sessions	n/a

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$452,935	2024-12-31	2025-04-21	10-K	0001213900-25-033608
2	assets	us-gaap:Assets	\$359,088	2024-12-31	2025-04-21	10-K	0001213900-25-033608
3	net income	us-gaap:NetIncomeLoss	-\$1.0M	2024-12-31	2025-04-21	10-K	0001213900-25-033608
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$289,802	2024-12-31	2025-04-21	10-K	0001213900-25-033608
5	assets	us-gaap:Assets	\$354,360	2023-12-31	2025-04-21	10-K	0001213900-25-033608
6	current assets	us-gaap:AssetsCurrent	\$165,257	2024-12-31	2025-04-21	10-K	0001213900-25-033608
7	current liabilities	us-gaap:LiabilitiesCurrent	\$1.1M	2024-12-31	2025-04-21	10-K	0001213900-25-033608
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$26.4M	2024-12-31	2025-04-21	10-K	0001213900-25-033608
9	operating income	us-gaap:OperatingIncomeLoss	-\$994,628	2024-12-31	2025-04-21	10-K	0001213900-25-033608
10	book equity	us-gaap:StockholdersEquity	-\$2.1M	2024-12-31	2025-04-21	10-K	0001213900-25-033608
11	liabilities	us-gaap:Liabilities	\$2.5M	2024-12-31	2025-04-21	10-K	0001213900-25-033608
12	operating income	us-gaap:OperatingIncomeLoss	-\$4.0M	2020-08-31	2021-12-13	10-K	0001213900-21-065002
13	interest expense	us-gaap:InterestExpense	\$535,688	2020-08-31	2021-12-13	10-K	0001213900-21-065002
14	revenue	us-gaap:Revenues	\$1.1M	2024-12-31	2025-04-21	10-K	0001213900-25-033608
15	revenue	us-gaap:Revenues	\$785,453	2023-12-31	2025-04-21	10-K	0001213900-25-033608
16	revenue	us-gaap:Revenues	\$3,407	2022-12-31	2024-04-18	10-K	0001213900-24-033935
17	revenue	us-gaap:Revenues	\$62,103	2019-08-31	2019-12-16	10-K	0001213900-19-026230
18	assets	us-gaap:Assets	\$409,591	2022-12-31	2024-04-18	10-K	0001213900-24-033935
19	assets	us-gaap:Assets	\$124,520	2021-08-31	2021-12-13	10-K	0001213900-21-065002
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,153,220	2025-03-27	2025-04-21	10-K	0001213900-25-033608
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,168,552	2024-03-31	2024-04-18	10-K	0001213900-24-033935